2014 – Invasion and Metastasis November 6th – 9th Ann Chambers, PhD Zena Werb, PhD University of Western Ontario University of California London, ON Canada San Francisco, CA Most cancer deaths are due to metastasis – the spread of cancer from its site of origin to distant, vital organs, and the physiological damage caused by tumor growth
CHAIRMEN Joan Brugge, Ph.D. Harvard Medical School Boston, MA Jeffrey Engelman MD, Ph.D. Massachusetts General Hospital Boston, MA OVERVIEW Cancer therapies that specifically target the genetic alterations associated with subsets of advanced cancers have shown impressive success in the clinic. Examples include ABL inhibitors fro chronic myelogenous leukemia, RAF inhibitors for BRAF mutant melanomas, EGFR
CHAIRMEN Lewis C. Cantley, PhD Beth Israel Deaconess Medical Center Boston, MA Eileen White, PhD The Cancer Institute of New Jersey New Brunswick, NJ OVERVIEW Oncogenic events that convert normal cells into cancer cells promote cell growth and proliferation and inactivate checkpoints that would normally block these functions in the absence
CHAIRMEN Scott Armstrong, MD, PhD Children’s Hospital, Harvard Medical School Boston, MA Steven Henikoff, PhD Fred Hutchinson Cancer Research Center Howard Hughes Medical Institute Seattle, WA OVERVIEW Cancer development is a multi-step process with mutations in proto-oncogenes and tumor suppressor genes playing a well-defined role. In this regard, cancer is a genetic disease.
This edition of the Forbeck Newsletter includes the 2010 Forum Summary on Cancer Genomics, as well as information about the 2011 on Epigenetics and Drugy Therapy and 2012 Tumor Metabolism Forums. There is also an update from the INRG (International Neuroblastoma Research Group.) Chairmen: Richard Kolodner, PhD; Prof. Michael R. Stratton, FRCPath I: Molecular